Follow us:

Linkedin Facebook X-twitter Instagram
Get started

Latest News

WINNER: National Sleep Foundation – Sleep Tech Award

Life Science Industry Awards

Kate Willis appointment

CEO Appointed Visiting Scholar at UC San Diego

CPO Joins the Shott Scale Up Accelerator Cohort

Neurovalens Win National Sleep Foundation’s 2024 SleepTech® Award

The National Sleep Foundation (NSF) Neurovalens as winners of the 2024 SleepTech® Award. NSF’s SleepTech Award recognizes the year’s most innovative efforts in advancing sleep technology and is a feature of NSF’s ongoing work to encourage and celebrate efforts when sleep science and insight are rapidly incorporated into accessible health products and services.

Our Type 2 Diabetes Clinical Trial Has Successfully Concluded!

The study tested the safety and effectiveness of a non-drug, non-invasive neurostimulation wearable device designed to help adults with Type 2 Diabetes improve their blood sugar control.

Neurovalens shines at the 2024 Life Science Industry Awards

We are delighted to have been awarded the Small Life Science Company of the Year at the 2024 Life Science Industry Awards, held in Dublin on the 27th of June. The event recognised the most innovative individuals and companies leading excellence in Ireland's life sciences sector.

Neurovalens Appoints Kate Willis as Vice President of Commercialization

Kate Willis has been appointed as the Vice President of Commercialization, where she will oversee the sales of Neurovalens' prescribed medical devices in the US and work towards securing reimbursement approvals from private healthcare insurance providers.

We're Hiring: Logistics Associate

Neurovalens is looking for an enthusiastic Logistics Associate to join our passionate and hard working team. This an exciting time for an ambitious individual to consider a career at Neurovalens.

Neurovalens CEO Appointed Visiting Scholar at UC San Diego

Neurovalens CEO, Dr. Jason McKeown has been appointed as a Visiting Scholar at the prestigious University of California, San Diego (UCSD), joining the Department of Psychiatry. This appointment marks a journey that began nearly a decade ago when Jason first collaborated with UCSD.

Neurovalens receives FDA clearance for medical device to treat anxiety

Modius Stress becomes company’s second product cleared for use in US. Neurovalens, a global leader in non-invasive neuro-technology, has received medical device clearance from the US Food & Drug Administration (FDA) to treat anxiety with its Modius Stress device

Celebrating Success: Neurovalens Triumphs at Digital DNA Awards 2024

Neurovalens were delighted to be awarded two recognitions at the 2024 Digital DNA awards in Belfast’s ICC, Waterfront on Thursday, March 21st. Small Tech Company of the Year and Highly Commended in the Tech For Good category.

Iain Hendrick (CPO) Joins the Shott Scale Up Accelerator Cohort for 2024

Building a high-performance team requires high performance leadership. Our Chief Project Officer, Iain Hendrick, will be spending the next 12 months on the Shott Scale Up Accelerator program with the Royal Academy of Engineering.

UK Innovation at Arab Health

Neurovalens were delighted to take our FDA Cleared Modius Sleep technology to Arab Health 2024, a Global Healthcare Medical Expo in Dubai from 29th January to 1st February 2024.

ISO 13485 Certified Medical Device Company

Neurovalens are an ISO 13485 certified medical device company. This is an international standard that sets out regulatory requirements for medical device quality management systems.

Neurovalens at 10 Downing Street

Our CEO, Jason McKeown was invited back to 10 Downing Street today to discuss our recently FDA cleared treatment for chronic insomnia.

Medica 2023

CPO Iain Hendrick and Software QA Manager Steven George attended Medica 2023 in Düsseldorf, Germany to showcase the newly FDA cleared Modius Sleep headset.

Neurovalens receives FDA clearance for medical device to treat insomnia

Neurovalens, a global leader in non-invasive neuro-technology, has received medical device clearance from the US Food & Drug Administration (FDA) to treat chronic insomnia with its Modius Sleep device.

Modius Spero - A non-invasive, drug-free technology being trialled as a potential treatment for PTSD

Neurovalens is studying the efficacy of a non-invasive electrical vestibular nerve stimulation (VeNS) device, the Modius Spero device, as a method of treating Post-Traumatic Stress Disorder (PTSD).

World Diabetes Day

Diabetes is a chronic disease, that causes blood sugar levels in your body to become too high, either due to your body not being able to respond properly to insulin or due to your body not being unable to produce any at all. If left untreated, this can lead to serious complications such as heart attack, stroke, obesity, eye disease, kidney disease and nerve damage.

How Sleep Deprivation Can Lead to Weight Gain

Sleep is an important factor to help maintain health and well-being. It’s recommended that an adult should get at least 7 hours of sleep a night. Getting a good night’s sleep has many benefits such as better memory, reduced stress levels and lowers the risk of heart disease.

Make Mental Health a Priority

There are nearly one billion people worldwide who suffer from mental disorders. There is a stigma surrounding mental health making it difficult to speak up and seek help. Covid 19 has been a huge impact on people's mental health all around the world. Within the first year of Covid-19, there has been a 25% increase in anxiety and depression worldwide.

Belfast Newsletter | Health tech company creates 22 new jobs

Belfast-based health tech company Neurovalens is set to create 22 new jobs with the development of a ground-breaking medical device. Neurovalens, a global leader of neuro-technology products, is embarking on the development of a device for the treatment of obesity with £1m support from Invest NI. The technology is based on the neuro stimulation of specific areas of the brain responsible for influencing appetite and cravings.

The Irish News | Latest cash injection sees medical tech firm Neurovalens target US growth

A BELFAST technology firm developing a number of specialised medical devices has received its second major cash injection in a month. Neurovalens has been boosted by £750,000 from the Growth Finance Fund to support the launch of a new sleep product in the USA later this year.

Featured in

Join the Neurovalens Mailing List

Keep up to date with our latest products, research and company news.

Neurovalens is a global health-tech company that creates non-invasive neurostimulation products used to solve some of the world’s greatest health challenges.

Our medical device technology offers unparalleled transdermal activation of the homeostatic nuclei of the brainstem and hypothalamus, allowing for alterations in autonomic function, circadian regulation and Neuro-metabolic influence.

Useful Links
Information